Stockreport

CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK [Yahoo! Finance]

CureVac N.V. - Ordinary Shares  (CVAC) 
PDF Study initiated following previously reported interim data from Phase 2 Part of combined Phase 1/2 study in seasonal influenza Composition of vaccine candidate change [Read more]